Viewing Study NCT00042965



Ignite Creation Date: 2024-05-05 @ 11:28 AM
Last Modification Date: 2024-10-26 @ 9:07 AM
Study NCT ID: NCT00042965
Status: COMPLETED
Last Update Posted: 2016-07-14
First Post: 2002-08-05

Brief Title: Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
Sponsor: Alliance for Clinical Trials in Oncology
Organization: Alliance for Clinical Trials in Oncology

Study Overview

Official Title: A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma
Status: COMPLETED
Status Verified Date: 2016-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug may kill more tumor cells

PURPOSE Phase II trial to study the effectiveness of combining capecitabine with gemcitabine in treating patients who have metastatic kidney cancer
Detailed Description: OBJECTIVES

Determine the objective response rate in patients with metastatic renal cell carcinoma treated with gemcitabine and capecitabine
Determine the duration of overall and progression-free survival of patients treated with this regimen
Determine the toxicity of this regimen in these patients

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
CDR0000069488 REGISTRY NCI Physician Data Query httpsreporternihgovquickSearchU10CA031946
U10CA031946 NIH None None